Celera says Abbott has selected two additional cancer targets for development

By Lisa Kerner

Erie, Pa., Feb. 15 - Celera Genomics Group, an Applera Corp. business, said Abbott has selected two Celera antigen targets for further investigation and potential therapeutic development.

This brings to six the total number of targets under investigation from the strategic collaboration established between the two companies to discover, develop and commercialize therapies for cancer treatment.

"We're delighted that Abbott has selected another two antigens for further investigation," Kathy Ordonez, Celera president, said in a company news release.

"We have performed outstanding work on our proteomics platform over the past few years, and we've made good progress towards discovering and validating targets in pancreatic, lung, colon, breast, gastric, prostate and renal cancers. The selection of four of these targets by Abbott in the last month further demonstrates the value of this platform for our current and potential partners."

Under the collaboration, a number of protein antigens identified and validated by Celera Genomics are being screened by Abbott, which may then select any for therapeutic development, the company said.

Celera may jointly fund clinical development and commercialization of any resulting therapeutic products. The company would share any financial returns resulting from commercialization, or receive milestone and royalty payments on successful therapies.

Abbott has responsibility for the commercialization of jointly funded collaboration products while Celera retains certain diagnostic rights associated with selected targets, the release stated.

Celera is focused on discovery, development and commercialization of diagnostic products as well as leveraging its proteomic, bioinformatic and genomic capabilities to identify and validate drug targets and pharmacogenomic markers. The company is located in Rockville, Md.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.